|
US7227010B2
(en)
*
|
1993-09-21 |
2007-06-05 |
United States Of America As Represented By The Secretary Of The Army |
Recombinant light chains of botulinum neurotoxins and light chain fusion proteins for use in research and clinical therapy
|
|
US8153397B2
(en)
*
|
1993-09-21 |
2012-04-10 |
The United States Of America As Represented By The Secretary Of The Army |
Recombinant light chains of botulinum neurotoxins and light chain fusion proteins for use in research and clinical therapy
|
|
US7037680B2
(en)
*
|
1993-09-21 |
2006-05-02 |
The United States Of America As Represented By The Secretary Of The Army |
Recombinant light chains of botulinum neurotoxins and light chain fusion proteins for use in research and clinical therapy
|
|
EP0878552A1
(en)
*
|
1997-05-13 |
1998-11-18 |
Erasmus Universiteit Rotterdam |
Molecular detection of chromosome aberrations
|
|
JP2002513587A
(ja)
*
|
1998-05-04 |
2002-05-14 |
ダコ エー エス |
染色体異常を検出するための方法およびプローブ
|
|
US20060216313A1
(en)
*
|
1999-08-10 |
2006-09-28 |
Allergan, Inc. |
Methods for treating a stricture with a botulinum toxin
|
|
US7491799B2
(en)
*
|
2000-07-21 |
2009-02-17 |
Allergan, Inc. |
Modified botulinum neurotoxins
|
|
US7691983B2
(en)
*
|
2000-07-21 |
2010-04-06 |
Allergan, Inc. |
Chimera botulinum toxin type E
|
|
US6903187B1
(en)
*
|
2000-07-21 |
2005-06-07 |
Allergan, Inc. |
Leucine-based motif and clostridial neurotoxins
|
|
US20030219462A1
(en)
*
|
2000-07-21 |
2003-11-27 |
Allergan Sales, Inc |
Clostridial neurotoxin compositions and modified clostridial neurotoxins
|
|
US20040220100A1
(en)
*
|
2000-07-21 |
2004-11-04 |
Essentia Biosystems, Inc. |
Multi-component biological transport systems
|
|
US7223577B2
(en)
|
2000-11-17 |
2007-05-29 |
Allergan, Inc. |
Post-translational modifications and Clostridial neurotoxins
|
|
US20020127247A1
(en)
*
|
2000-11-17 |
2002-09-12 |
Allergen Sales, Inc. |
Modified clostridial neurotoxins with altered biological persistence
|
|
US8022172B2
(en)
*
|
2001-08-28 |
2011-09-20 |
Allergan, Inc. |
Luminescence resonance energy transfer (LRET) assays for clostridial toxin activity
|
|
US7374896B2
(en)
*
|
2001-08-28 |
2008-05-20 |
Allergan, Inc. |
GFP-SNAP25 fluorescence release assay for botulinum neurotoxin protease activity
|
|
US7332567B2
(en)
*
|
2001-08-28 |
2008-02-19 |
Allergan, Inc. |
Fret protease assays for clostridial toxins
|
|
US20040115727A1
(en)
*
|
2002-12-11 |
2004-06-17 |
Allergan, Inc., A Corporation |
Evolved clostridial toxins with altered protease specificity
|
|
US20040226556A1
(en)
|
2003-05-13 |
2004-11-18 |
Deem Mark E. |
Apparatus for treating asthma using neurotoxin
|
|
US20050191321A1
(en)
*
|
2004-02-26 |
2005-09-01 |
Allergan, Inc. |
Methods for treating headache
|
|
US9211248B2
(en)
|
2004-03-03 |
2015-12-15 |
Revance Therapeutics, Inc. |
Compositions and methods for topical application and transdermal delivery of botulinum toxins
|
|
CN1946431B
(zh)
|
2004-03-03 |
2011-12-07 |
雷文斯治疗公司 |
用于肉毒毒素的局部施用和透皮递送的组合物和方法
|
|
CA2558676C
(en)
|
2004-03-03 |
2019-04-16 |
Essentia Biosystems, Inc. |
Compositions and methods for topical diagnostic and therapeutic transport
|
|
US20060024331A1
(en)
*
|
2004-08-02 |
2006-02-02 |
Ester Fernandez-Salas |
Toxin compounds with enhanced membrane translocation characteristics
|
|
US7399607B2
(en)
|
2004-09-22 |
2008-07-15 |
Allergan, Inc. |
Fluorescence polarization assays for determining clostridial toxin activity
|
|
JP4994241B2
(ja)
|
2004-11-22 |
2012-08-08 |
ニューヨーク・ユニバーシティ |
遺伝子操作されたクロストリジウム遺伝子、操作された遺伝子によりコードされるタンパク質、およびその使用
|
|
SG160357A1
(en)
*
|
2005-03-03 |
2010-04-29 |
Revance Therapeutics Inc |
Compositions and methods for topical application and transdermal delivery of botulinum toxins
|
|
EP1871789B1
(en)
|
2005-03-15 |
2013-11-06 |
Allergan, Inc. |
Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells
|
|
NZ568216A
(en)
*
|
2005-11-17 |
2012-09-28 |
Revance Therapeutics Inc |
Compositions and methods of topical application and transdermal delivery of botulinum toxins with reduced non-toxin proteins
|
|
EP1834962A1
(de)
|
2006-03-15 |
2007-09-19 |
Biotecon Therapeutics GmbH |
PEGyliertes mutiertes Clostridium botulinum Toxin
|
|
EP2505592A1
(en)
|
2006-07-11 |
2012-10-03 |
Allergan, Inc. |
Modified clostridial toxins with enhanced translocation capability and enhanced targeting activity
|
|
NZ598159A
(en)
*
|
2006-12-29 |
2013-08-30 |
Revance Therapeutics Inc |
Transport molecules using reverse sequence hiv-tat polypeptides
|
|
JP2010514781A
(ja)
*
|
2006-12-29 |
2010-05-06 |
ルバンス セラピュティックス インク． |
Ｈｉｖ−ｔａｔに由来するポリペプチド断片を用いて安定化されるボツリヌス毒素を局所適用及び経皮送達する組成物及び方法
|
|
US8483831B1
(en)
|
2008-02-15 |
2013-07-09 |
Holaira, Inc. |
System and method for bronchial dilation
|
|
US8088127B2
(en)
|
2008-05-09 |
2012-01-03 |
Innovative Pulmonary Solutions, Inc. |
Systems, assemblies, and methods for treating a bronchial tree
|
|
EP2337790B1
(en)
|
2008-08-29 |
2016-07-13 |
Merz Pharma GmbH & Co. KGaA |
Clostridial neurotoxins with altered persistency
|
|
GB0903913D0
(en)
*
|
2009-03-06 |
2009-04-22 |
Medical Res Council |
Compositions and methods
|
|
ES2770033T3
(es)
*
|
2009-03-13 |
2020-06-30 |
Allergan Inc |
Ensayos de actividad de endopeptidasa redirigida basados en inmunología
|
|
US20100303783A1
(en)
*
|
2009-05-29 |
2010-12-02 |
Allergan, Inc. |
Methods of Treating Urogenital-Neurological Disorders Using Tachykinin Retargeted Endopepidases
|
|
US20100303788A1
(en)
*
|
2009-05-29 |
2010-12-02 |
Allergan, Inc. |
Methods of Treating Chronic Neurogenic Inflammation Using Galanin Retargeted Endopepidases
|
|
US20100303794A1
(en)
|
2009-05-29 |
2010-12-02 |
Allergan, Inc. |
Methods of Treating Urogenital-Neurological Disorders Using Glucagon Like Hormone Retargeted Endopepidases
|
|
US20100303757A1
(en)
|
2009-05-29 |
2010-12-02 |
Allergan, Inc. |
Methods of Treating Chronic Neurogenic Inflammation Using Interleukin Retargeted Endopepidases
|
|
BRPI1014253A2
(pt)
*
|
2009-07-02 |
2016-04-12 |
Merz Pharma Gmbh & Co Kgaa |
polinucleotídeo codificado um polipeptídeo de neurotoxina, vetor, célula hospedeira, anticorpo, uso de um polinucleotídeo, método para a fabricação de um polipeptídeo de neurotoxina e método para a fabricação de um medicamento
|
|
WO2011018665A1
(en)
*
|
2009-08-12 |
2011-02-17 |
Medical Research Council |
Complexing system
|
|
WO2011041779A1
(en)
|
2009-10-02 |
2011-04-07 |
Allergan, Inc. |
In vitro method of determining changes in a protein environment
|
|
AU2010315396B2
(en)
|
2009-10-27 |
2016-05-05 |
Nuvaira, Inc |
Delivery devices with coolable energy emitting assemblies
|
|
US8911439B2
(en)
|
2009-11-11 |
2014-12-16 |
Holaira, Inc. |
Non-invasive and minimally invasive denervation methods and systems for performing the same
|
|
JP6000851B2
(ja)
|
2009-11-11 |
2016-10-05 |
ホライラ， インコーポレイテッド |
組織治療および狭窄制御のためのシステム、装置、および方法
|
|
KR20120107988A
(ko)
|
2009-12-16 |
2012-10-04 |
알러간, 인코포레이티드 |
통합된 프로테아제 절단 부위 결합 도메인을 포함하는 변형 클로스트리듐 독소
|
|
SI2684890T1
(sl)
|
2010-01-25 |
2016-10-28 |
Allergan, Inc. |
Metode znotrajcelične pretvorbe enoverižnih beljakovin v njihovo dvoverižno obliko
|
|
WO2011091419A2
(en)
*
|
2010-01-25 |
2011-07-28 |
New York Universiy |
Recombinant derivatives of botulinum neurotoxins engineered for trafficking studies and neuronal delivery
|
|
US8916162B2
(en)
*
|
2010-02-20 |
2014-12-23 |
Alexey Gennadievich Zdanovsky |
Botulinum neurotoxin antigenic compositions and methods
|
|
RU2561465C2
(ru)
|
2010-05-20 |
2015-08-27 |
Аллерган, Инк. |
Разрушаемые клостридиальные токсины
|
|
US20120251574A1
(en)
*
|
2011-03-28 |
2012-10-04 |
Allergan, Inc. |
Endopeptidase and Neurotoxin Combination Treatment of Multiple Medical Conditions
|
|
AU2012292163A1
(en)
*
|
2011-08-04 |
2014-02-27 |
Merz Pharma Gmbh & Co. Kgaa |
Alteration of proteolytic cleavage of botulinum neurotoxins
|
|
MX351012B
(es)
*
|
2011-11-09 |
2017-09-28 |
Merz Pharma Gmbh & Co Kgaa |
Neurotoxinas que exhiben actividad biologica acortada.
|
|
CA2889833A1
(en)
|
2012-10-28 |
2014-05-01 |
Revance Therapeutics, Inc. |
Compositions and methods for safe treatment of rhinitis
|
|
US20150322118A1
(en)
*
|
2012-12-05 |
2015-11-12 |
Merz Pharma Gmbh & Co. Kgaa |
Recombinant clostridial neurotoxins with enhanced membrane localization
|
|
US9398933B2
(en)
|
2012-12-27 |
2016-07-26 |
Holaira, Inc. |
Methods for improving drug efficacy including a combination of drug administration and nerve modulation
|
|
WO2014117148A1
(en)
|
2013-01-28 |
2014-07-31 |
New York University |
Treatment methods using atoxic neurotoxin derivatives
|
|
GB201312317D0
(en)
|
2013-07-09 |
2013-08-21 |
Syntaxin Ltd |
Cationic neurotoxins
|
|
KR102272580B1
(ko)
*
|
2013-07-30 |
2021-07-05 |
메르츠 파마 게엠베하 운트 코. 카가아 |
보툴리눔 독소의 고순도 신경독성 성분의 제조 방법 및 이의 용도
|
|
CN105683212B
(zh)
*
|
2013-08-21 |
2020-03-17 |
香港理工大学 |
高催化活性的基因改造梭菌属神经毒素
|
|
ES2704237T3
(es)
|
2014-03-05 |
2019-03-15 |
Merz Pharma Gmbh & Co Kgaa |
Nuevas neurotoxinas clostridiales recombinantes con un aumento de la duración del efecto
|
|
US11484580B2
(en)
|
2014-07-18 |
2022-11-01 |
Revance Therapeutics, Inc. |
Topical ocular preparation of botulinum toxin for use in ocular surface disease
|
|
EP3230457B1
(en)
|
2014-12-09 |
2021-06-30 |
New York University |
Clostridial neurotoxin fusion proteins, propeptide fusions, their expression, and use
|
|
CN107108703B
(zh)
|
2015-01-09 |
2022-09-23 |
益普生生物创新有限公司 |
阳离子神经毒素
|
|
US10676723B2
(en)
|
2015-05-11 |
2020-06-09 |
David Gordon Bermudes |
Chimeric protein toxins for expression by therapeutic bacteria
|
|
TW201718627A
(zh)
|
2015-06-11 |
2017-06-01 |
梅茲製藥有限兩合公司 |
重組梭菌神經毒素及其使用與形成方法、包括其之醫藥組合物及對應其之前驅物、編碼前驅物之核酸序列及其獲得方法與前驅物之形成方法、載體與包括核酸序列之重組宿主細胞
|
|
GB201517450D0
(en)
|
2015-10-02 |
2015-11-18 |
Ipsen Biopharm Ltd |
Method
|
|
US11078472B2
(en)
|
2016-01-20 |
2021-08-03 |
Merz Pharma Gmbh & Co., Kgaa |
Recombinant clostridial neurotoxins with increased duration of effect
|
|
MX395130B
(es)
|
2016-03-02 |
2025-03-24 |
Merz Pharma Gmbh & Co Kgaa |
Composicion que comprende toxina botulinica
|
|
GB201607901D0
(en)
*
|
2016-05-05 |
2016-06-22 |
Ipsen Biopharm Ltd |
Chimeric neurotoxins
|
|
TW201814045A
(zh)
|
2016-09-16 |
2018-04-16 |
英商艾普森生物製藥有限公司 |
製造雙鏈梭狀芽孢桿菌神經毒素之方法
|
|
WO2018060351A1
(en)
|
2016-09-29 |
2018-04-05 |
Ipsen Biopharm Limited |
Hybrid neurotoxins
|
|
US11129906B1
(en)
|
2016-12-07 |
2021-09-28 |
David Gordon Bermudes |
Chimeric protein toxins for expression by therapeutic bacteria
|
|
WO2018233813A1
(en)
|
2017-06-20 |
2018-12-27 |
Merz Pharma Gmbh & Co. Kgaa |
Novel recombinant botulinum toxin with increased duration of effect
|
|
ES2930237T3
(es)
|
2017-07-06 |
2022-12-09 |
Merz Pharma Gmbh & Co Kgaa |
Neurotoxinas botulínicas recombinantes nuevas con mayor duración de efectos
|
|
WO2019101308A1
(en)
|
2017-11-22 |
2019-05-31 |
Merz Pharma Gmbh & Co. Kgaa |
Novel recombinant botulinum toxin with increased duration of effect
|
|
WO2019243376A1
(en)
|
2018-06-18 |
2019-12-26 |
Ipsen Biopharm Limited |
Intramuscular injection of botulinum toxin for the treatment of vulvodynia
|
|
JP7604365B2
(ja)
|
2018-09-28 |
2024-12-23 |
イプセン バイオファーム リミテッド |
細胞ベースのクロストリジウム神経毒アッセイ
|
|
GB201815817D0
(en)
|
2018-09-28 |
2018-11-14 |
Ispen Biopharm Ltd |
Clostridial neurotoxins comprising and exogenous activation loop
|
|
GB201815844D0
(en)
|
2018-09-28 |
2018-11-14 |
Ipsen Biopharm Ltd |
Therapeutic & comestic uses of botulinum neurotoxin serotype e
|
|
US12162912B2
(en)
|
2018-11-21 |
2024-12-10 |
The Regents Of The University Of Colorado, A Body Corporate |
Proteins for blocking neurotransmitter release
|
|
GB201900621D0
(en)
|
2019-01-16 |
2019-03-06 |
Ipsen Biopharm Ltd |
Labelled polypeptides
|
|
GB201907016D0
(en)
|
2019-05-17 |
2019-07-03 |
Ipsen Biopharm Ltd |
Screening method to determine suitability for participation in a clinical trial
|
|
GB201914034D0
(en)
|
2019-09-30 |
2019-11-13 |
Ipsen Biopharm Ltd |
Treatment of neurological disorders
|
|
GB202001353D0
(en)
|
2020-01-31 |
2020-03-18 |
Ipsen Biopharm Ltd |
Treatment of skin conditions
|
|
GB202100566D0
(en)
|
2021-01-15 |
2021-03-03 |
Ipsen Biopharm Ltd |
Treatment of brain damage
|
|
GB202103372D0
(en)
|
2021-03-11 |
2021-04-28 |
Ipsen Biopharm Ltd |
Modified clostridial neurotoxins
|
|
GB202104294D0
(en)
|
2021-03-26 |
2021-05-12 |
Ipsen Biopharm Ltd |
Clostridial neurotoxins comprising an exogenous activation loop
|
|
KR20230001260A
(ko)
*
|
2021-06-28 |
2023-01-04 |
(주)메디톡스 |
재조합 보툴리눔 독소 타입 a 경쇄, 재조합 보툴리눔 독소 및 이의 조성물, 용도 및 방법
|
|
GB202116795D0
(en)
|
2021-11-22 |
2022-01-05 |
Ipsen Biopharm Ltd |
Treatment of visceral pain
|
|
GB202214232D0
(en)
|
2022-09-28 |
2022-11-09 |
Ispen Biopharm Ltd |
Clostridial neurotoxins comprising an activating exogenous protease cleavage site
|
|
GB202214229D0
(en)
|
2022-09-28 |
2022-11-09 |
Ipsen Biopharm Ltd |
Clostridial neurotoxins comprising an activating endosomal protease cleavage site
|
|
CH720444A2
(de)
*
|
2023-01-20 |
2024-07-31 |
Abbvie Inc |
Clostridium botulinum serotyp a neurotoxin (bont/a)- sequenzvarianten
|
|
GB202318884D0
(en)
|
2023-12-11 |
2024-01-24 |
Ipsen Biopharm Ltd |
Formulation
|